Compass-Logo-Black++(1).png
Compass Pathways appoints Teri Loxam as Chief Financial Officer
December 07, 2023 07:00 ET | Compass Pathways
LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass-Logo-Black++(1).png
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
December 06, 2023 16:00 ET | Compass Pathways
LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass-Logo-Black++(1).png
Compass Pathways to participate in upcoming Evercore investor conference
November 24, 2023 08:00 ET | Compass Pathways
LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
November 15, 2023 04:00 ET | Compass Pathways
UK sites to participate in part of pivotal phase 3 program following Medicines and Healthcare Regulatory Agency approval of study Research will take place in the UK, including at the newly opened...
compass_positive_tagline-01.png
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
November 02, 2023 07:00 ET | COMPASS Pathways
Highlights: COMP360 Phase 3 pivotal program ongoing with expanding European clinical sitesSecured up to $285 million private placement financing with $125 million upfrontCash position at September 30,...
compass_positive_tagline-01.png
COMPASS Pathways announces CFO transition
October 26, 2023 08:00 ET | COMPASS Pathways
LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient access to evidence-based...
compass_positive_tagline-01.png
COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023
October 24, 2023 16:01 ET | COMPASS Pathways
LONDON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
compass_positive_tagline-01.png
COMPASS Pathways appoints Daphne Karydas to its Board of Directors
September 18, 2023 16:31 ET | COMPASS Pathways
LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
compass_positive_tagline-01.png
COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
September 06, 2023 04:00 ET | COMPASS Pathways
LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
compass_positive_tagline-01.png
COMPASS Pathways to participate in upcoming September investor conferences
August 29, 2023 16:30 ET | COMPASS Pathways
LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...